A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on One to Three Glucose-lowering Agents
Latest Information Update: 18 Aug 2025
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Oramed Pharmaceuticals
Most Recent Events
- 03 Aug 2025 Planned End Date changed from 22 May 2026 to 22 May 2027.
- 03 Aug 2025 Planned primary completion date changed from 25 Apr 2026 to 25 Apr 2027.
- 03 Aug 2025 Planned initiation date changed from 15 Mar 2025 to 15 Dec 2025.